Aarti Drugs Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9pj23cq8zyd6kwfiplg9onkm.pdf

Key Takeaways


Methylamine Plant & Metformin Backward Integration

Adhish Patil: "I believe now we are the only ones as of today with a backward integration facility. So, that puts us in a very good position."

Salicylic Acid: Shutdown, Restart Conditions & Forward Integration

Adhish Patil: "Unless we install that equipment, there is no point in going ahead with higher production of salicylic acid because then that will, in turn, cause more losses for us."

Sayakha Plant Ramp-Up


Regulated-Market & Formulation Push


Margins, Costs & the War Overhang

Adhish Patil: "Had this war not been there, our earlier targets were definitely 14% to 14.5% EBITDA margin for FY 2027."

Volume, Pricing & Demand Outlook

Adhish Patil: "If the crude prices remain elevated very high, then the older generation molecules, which are already being sold at a very cheaper rate in the Indian market, and there is some kind of price regulation for the formulation players... when the API become very expensive, typically, the demand of those products goes down."

Guidance & Commitments

CommitmentSpecificsTimeline
Methylamine plant utilizationCross 55–60%, then operate above 70%June quarter / within a year
Sayakha plant profitabilityReal profitability to start showing resultsWithin 3–4 months
EBITDA margin13.5% to 14%FY27
US API flows from reapproved plantFlows to start for antibiotic, anti-inflammatory and other therapiesWithin 12–18 months
Formulation quarterly run rateINR90 crores maintainedFY27
Formulation revenue targetAt least INR1,000 croresNext 3–5 years
CapexINR300–400 crores; could be higher if Sayakha and salicylic acid cash flow improves starklyNext 2–3 years
CWIP amortization (formulation)Most starts amortizing; major chunk post 24 monthsOver next 24 months
Salicylic acid derivatives plantCommissioned and operationalEnd of May / mid-June

Key Metrics

MetricQ4 FY26
Consolidated revenue₹721.1 cr, +6% YoY and +20% QoQ
Consolidated EBITDA₹96.6 cr, flattish YoY and +72% QoQ
EBITDA margin13.4%
Consolidated PAT₹55.3 cr, -12% YoY and +36% QoQ
PAT margin7.7%
Standalone revenue₹631.7 cr, vs ₹623.0 cr in Q4 FY25
Standalone domestic revenue growth+7% YoY
Standalone export revenue growth-7% YoY
Formulation revenue₹91.3 cr, +41% YoY; exports contributed 69%
FY26 formulation revenue₹330.5 cr, +16% YoY; exports contributed 65%
API antibiotic share of API sales37.8%
API anti-protozoal share of API sales19.6%
API anti-inflammatory share of API sales11.9%
API antidiabetic share of API sales15.0%
API anti-fungal share of API sales10.0%
Exports contribution to consolidated revenue38% in FY26, up from 35% in FY25
Regulated market share of exports73% in FY26, up from 66% in FY25
Methylamine plant production rate~1,000 tonnes per month in March 2026
Methylamine plant utilization~40% in Q4 FY26, up from ~29% in Q3 FY26
Methylamine plant utilization target55%–60% expected in Q1 FY27, upwards of 70% within a year
Formulation business EBITDA margin16%–17%, consistent for last two quarters
FY27 EBITDA margin target13.5%–14.0%; earlier pre-war target was 14.0%–14.5%
Capex plan₹300 cr–₹400 cr over next two to three years
Formulation business revenue target₹1,000 cr in next three to five years
Consolidated long-term debt₹328 cr
Consolidated short-term debt₹248 cr
CWIP₹214 cr
Total EBITDA loss from new projects in FY26₹18 cr–₹20 cr